IAP

PLAYSTUDIOS Acquires Mobile Casual Game Studio Brainium, Adding a Rich Suite of Popular Games to the Company’s Portfolio

Retrieved on: 
Thursday, October 13, 2022
Electronic Games, Entertainment, Mobile Entertainment, MAU, U.S. Securities and Exchange Commission, Interest, SEC, Webcast, Active users, Solitaire, Growth, EVP, Cruise line, NASDAQ, Slot, Resorts World, IHG Hotels & Resorts, MGM Resorts International, Corporation, POP, Private Securities Litigation Reform Act, Industry, Acquisition, DAU, Blackjack, Q&A, CEO, Norwegian Cruise Line, Business development, Advertising, Calendar, Bingo, ID, IAP, Video game, Professor Brainium's Games, Sudoku

The acquisition adds a rich suite of popular casual games, such as Solitaire, Spider Solitaire, Sudoku, and Mahjong, to PLAYSTUDIOS best-in-class game portfolio, and more than doubles the companys average daily active users, enhancing the reach and appeal of its playAWARDS platform to players and rewards partners.

Key Points: 
  • The acquisition adds a rich suite of popular casual games, such as Solitaire, Spider Solitaire, Sudoku, and Mahjong, to PLAYSTUDIOS best-in-class game portfolio, and more than doubles the companys average daily active users, enhancing the reach and appeal of its playAWARDS platform to players and rewards partners.
  • The acquisition of Brainium brings a suite of thoughtfully designed and highly engaging casual games to PLAYSTUDIOS.
  • Brainium, a passionate, Portland-based team of creative game designers and engineers, will retain its brand name and leadership team as part of PLAYSTUDIOS.
  • Founded by a team of veteran gaming, hospitality, and technology entrepreneurs, PLAYSTUDIOS apps combine the best elements of popular casual games with compelling real-world experiences.

AppsFlyer’s 15th Performance Index Finds Market Conditions and Privacy Changes Continue to Disrupt App Marketers and Media Companies

Retrieved on: 
Wednesday, October 12, 2022
Social Media, Influencer, Search Engine Optimization, Search Engine Marketing, Content Marketing, Other Communications, Technology, Marketing, Advertising, Communications, Apps, Applications, Professional Services, Other Technology, Media, Software, Data Analytics, Risk, Efficiency, Meta, ATT, Kovats retention index, Privacy, ASA, Business, IronSource, Technology, Budget, Acquisition, AppsFlyer, Ecosystem, IOS, IAP, Video game console, Video game, Mobile phone, SKAN, Android, Google, Q2, TikTok

All of these changes for marketers and media companies have presented multiple opportunities.

Key Points: 
  • All of these changes for marketers and media companies have presented multiple opportunities.
  • The aftershocks created by Apples App Tracking Transparency (ATT) framework continue to generate major challenges for app marketers and media companies alike.
  • The unique market conditions that have emerged in 2022 have deepened the challenges mobile marketers and mobile media sources are facing.
  • AppsFlyers Performance Index analyzed a total of over 500 media sources, 27 billion installs, and over 19,000 apps from January to June 2022.

Synthetic Biologics Rebrands as Theriva Biologics

Retrieved on: 
Wednesday, October 12, 2022
Potyvirus, Time, PDAC, Therapy, Sale, SEC, HCT, Growth, Neoplasm, Synthetic biological circuit, CGMP, NYSE, CDI, Patient, IV, Form 8-K, Initiation, AMR, Degenerative disease, VCN, Brain, Clinical, Private Securities Litigation Reform Act, University, NYSE American, Company, Immune system, Marketing, Acquisition, Clostridioides difficile infection, Safety, Clinical trial, SYN, GLOBE, Maintenance, OA, Terminology, IAP, Cancer, Pharmaceutical industry, Vaccine, American

ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), (Theriva or the Company) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN).

Key Points: 
  • ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), (Theriva or the Company) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN).
  • The rebranding solidifies our strategic transformation and reflects our sharpened focus on advancing unique, oncolytic viruses optimized for IV administration, said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
  • Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need.
  • For more information, please visit Theriva Biologics' website at www.therivabio.com .

SHAREit expands market share in Nordic countries - offering advertisers a new global audience

Retrieved on: 
Wednesday, October 12, 2022
Growth, Woman, SHAREit, Supercell, Family, Video, Mouth, Region, Goal, Friends, Marketing, Science and technology in Asia, Group, OTT, Ageing, Heart, Ubisoft, IAP, Video game, Gameloft, EU

Known especially in the gaming community as a go-to platform, SHAREit's business network spans over 150 countries in 45 languages.

Key Points: 
  • Known especially in the gaming community as a go-to platform, SHAREit's business network spans over 150 countries in 45 languages.
  • SHAREit is now expanding its operations from Asia, Middle East, Africa and South America to the UK and the EU.
  • SHAREit Group's mission is to make digital content accessible to all, especially for people in emerging markets.
  • Arunabh Madhur, Regional VP and Head Business EMEA at SHAREit Group says: "SHAREit is a gateway to the emerging markets.

ClickStream Subsidiary HeyPal™ Social Language Learning App Paid Subscriptions Hits 5% In-App Purchase Rate

Retrieved on: 
Thursday, October 6, 2022
Lifestyle, Education, Technology, Other Communications, Communications, Social Media, Apps, Applications, Software, Internet, Consumer, Other Education, Adoption, Happy path, Android, Friends, Industry, CEO, IOS, OTC, Forward-looking statement, Terminology, IAP, Mobile phone, Risk management

ClickStream Corp. (OTC PINK: CLIS) announces updated performance metrics for its subsidiary company, Nebula Software Corp. and its flagship social language learning app, HeyPal .

Key Points: 
  • ClickStream Corp. (OTC PINK: CLIS) announces updated performance metrics for its subsidiary company, Nebula Software Corp. and its flagship social language learning app, HeyPal .
  • HeyPals Premium subscriptions year-to-date has reached 656 subscribers, representing a 5% in-app purchase rate (IAP) of iOS and Android users, which is above the industry average of 2-3%.
  • HeyPal Premium learning and connecting tools continue to see rapid adoption as users match with study buddies, and leverage Predictive Texting in other languages to kickstart conversations among new friends.
  • Jonathan Maxim, CEO of HeyPal, states, Were excited to see people engaging with the new Premium Features.

Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma

Retrieved on: 
Friday, September 30, 2022
IAP, Synthetic biological circuit, Director general, Therapy, Time, Safety, Trial of the century, Carboplatin, Synthetic, IV, NYSE, Sale, CGMP, Retinoblastoma, Clostridioides difficile infection, Company, Acquisition, Growth, AMR, Private Securities Litigation Reform Act, VCN, Maintenance, Neoplasm, Patient, SIOP, Terminology, Annual report, SYN, International Society, Melphalan, Topotecan, Cancer, Form 8-K, Marketing, SEC, GLOBE, Congress, HCT, CDI, Degenerative disease, Pharmaceutical industry, Holding company, Vaccine

Preclinical results were featured in an oral presentation at the SIOP 2022 Congress of the International Society of Pediatric Oncology, being held in Barcelona, Spain from September 28-October 1, 2022.

Key Points: 
  • Preclinical results were featured in an oral presentation at the SIOP 2022 Congress of the International Society of Pediatric Oncology, being held in Barcelona, Spain from September 28-October 1, 2022.
  • The exciting new data presented at SIOP demonstrate that administration of VCN-01 in combination with topotecan chemotherapy may improve VCN-01 activity against retinoblastoma, said Manel Cascall, Ph.D., General Director of Synthetic Biologics European Subsidiary.
  • Sequential administration of intratumoral VCN-01 followed by systemic topotecan significantly increased median ocular survival, compared to VCN-01 alone (p =0.0364).
  • Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need.

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Retrieved on: 
Tuesday, September 27, 2022
Data, Synthetic biological circuit, Piperacillin/tazobactam, Safety, Meropenem, Clostridioides difficile infection, GI, Infection, Patient, Clinical trial, Form 8-K, Absorption, Washington University School of Medicine, Cohort, Time, IV, Sale, Sepsis, CGMP, Clostridioides, Company, Acquisition, Growth, Washington University School of Law, AES, Annual report, SYN, SEC, HCT, CDI, ECL, NYSE, Risk, Population, VCN, Review, Neoplasm, VRE, SAE, GLOBE, Marketing, Șaeș, Plasma, IAP, Therapy, Cefepime, Washington University in St. Louis, AMR, Private Securities Litigation Reform Act, Maintenance, DSMC, Terminology, Pharmacokinetics, Fever, Degenerative disease, Pharmaceutical industry, Antibiotics

ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of results from the first Cohort of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).

Key Points: 
  • A total of 13 SAEs were reported among 10 patients, with the most common SAE being infections and infestations including sepsis.
  • None of the three ECL positive plasma samples were found to contain active SYN-004 using a functional enzyme activity assay.
  • The ongoing randomized, double-blinded, placebo-controlled Phase 1b/2a clinical trial is being conducted at Washington University School of Medicine in St. Louis.
  • A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis.

Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care

Retrieved on: 
Wednesday, September 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Tao, Safety, Research, Multiple sclerosis, Sun, Standard of care, Dysphagia, Health, Science, Cisplatin, Lancet, Odds ratio, Radiation, Head and Neck Cancer Alliance, Electronics, Merck, Neutropenia, Risk, Mucositis, Congress, Patient, Merck Millipore, Cancer, Survival, Chemoradiotherapy, IAP, OS, Death, Head, Incidence, Food, Intelligence, CRT, LA, Progression-free survival, Oncology, Gene editing, Recurrence, HR, Teaching hospital, University Hospital (Newark, New Jersey), Speech, Probability, Management, Entrepreneurship, Infertility, X-ray, Sleep, Mortality, Merck Serono, Anemia, Phase, Neck, Veni, vidi, vici, The Lancet, Merck Group, EMD, Apoptosis, Life, Abstract, Pharmaceutical industry, Dietary supplement, Debiopharm

There is a clear need for improved treatment options for patients with unresected locally advanced head and neck cancer.

Key Points: 
  • There is a clear need for improved treatment options for patients with unresected locally advanced head and neck cancer.
  • Median OS was prolonged with xevinapant (median not reached; 95% CI, 40.3 months-not evaluable) versus placebo (36.1 months; 95% CI, 21.8-46.7 months).
  • Treatment with xevinapant nearly doubled OS, with a 53% (95% CI, 37-66%) probability of survival after five years compared with 28% (95% CI, 15-42%) with placebo.
  • Adverse events of grade 3 or higher were reported in 41 (85%) of 48 patients in the xevinapant group and 41 (87%) of 47 patients in the placebo group.

Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care

Retrieved on: 
Wednesday, September 7, 2022
Oncology, Health, Genetics, Clinical Trials, Radiology, Biotechnology, Tao, Safety, Sun, Standard of care, Dysphagia, Health, Science, Cisplatin, Lancet, Odds ratio, Radiation, Head and Neck Cancer Alliance, Electronics, Neutropenia, Risk, Mucositis, Congress, Patient, Merck Millipore, Survival, Chemoradiotherapy, IAP, OS, Death, Head, Incidence, Food, Intelligence, CRT, LA, Progression-free survival, Cancer, Oncology, Gene editing, Recurrence, HR, Teaching hospital, University Hospital (Newark, New Jersey), Speech, Probability, Management, Entrepreneurship, X-ray, Sleep, Mortality, Merck Serono, Anemia, Phase, Neck, Veni, vidi, vici, The Lancet, III, Apoptosis, Abstract, Pharmaceutical industry, Dietary supplement, Merck, Debiopharm

There is a clear need for improved treatment options for patients with unresected locally advanced head and neck cancer.

Key Points: 
  • There is a clear need for improved treatment options for patients with unresected locally advanced head and neck cancer.
  • Median OS was prolonged with xevinapant (median not reached; 95% CI, 40.3 months-not evaluable) versus placebo (36.1 months; 95% CI, 21.8-46.7 months).
  • Treatment with xevinapant nearly doubled OS, with a 53% (95% CI, 37-66%) probability of survival after five years compared with 28% (95% CI, 15-42%) with placebo.
  • Adverse events of grade 3 or higher were reported in 41 (85%) of 48 patients in the xevinapant group and 41 (87%) of 47 patients in the placebo group.

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Retrieved on: 
Monday, September 5, 2022
SYN, IV, Maintenance, Poster, Clostridioides difficile infection, ESMO, AMR, Synthetic, Director general, GLOBE, Company, Congress, PD-L1, Patient, IAP, Time, Head, Sale, SEC, CGMP, Oncology, Pharmacokinetics, Terminology, Degenerative disease, Institute, Neoplasm, HCT, Private Securities Litigation Reform Act, Acquisition, Growth, Marketing, NYSE, Form 8-K, CD8, Efficacy, CDI, Neck, PD, Retinoblastoma, Therapy, CEST, Toxicology, Annual report, VCN, Pharmaceutical industry, Vaccine, Medical imaging, Tolerability, Safety, Durvalumab, Fever

ROCKVILLE, Md., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a presentation of initial data from a Phase 1 investigator-sponsored study evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). Data will be featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, being held both virtually and in Paris from September 9-13, 2022.

Key Points: 
  • Data will be featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, being held both virtually and in Paris from September 9-13, 2022.
  • Further, these results provide valuable dose-finding context and build upon our compelling foundation of data that highlight VCN-01s differentiated mechanism of action that may transform cancer therapy.
  • Pharmacokinetics (PK) and pharmacodynamics (PD): Based on toxicology and PK/PD analysis the recommended Phase 2 dose is 1x1013 viral particles (vp)/patient.
  • Biological activity: Sustained blood levels of VCN-01 viral genomes and increased serum hyaluronidase levels were maintained for over six weeks.